Rebus (RBSH) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document Information [Line Items]
Entity Registrant Name	GENSPERA INC
Entity Central Index Key	1421204
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	GNSZ
Entity Common Stock, Shares Outstanding		33,548,366
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$1,403	$2,316
Prepaid expenses	160	197
Total current assets	1,563	2,513
Office equipment, net of accumulated depreciation of $24 and $23	15	12
Intangible assets, net of accumulated amortization of $115 and $111	97	101
Other assets	3	3
Total assets	1,678	2,629
Current liabilities:
Accounts payable	1,209	989
Accrued expenses	1,713	1,438
Convertible notes - stockholder	105	105
Total current liabilities	3,027	2,532
Total liabilities	3,027	2,532
Commitments and contingencies
Stockholders’ equity (deficit):
Preferred stock, par value $0.0001 per share; 30,000,000 shares authorized, none issued and outstanding	0	0
Common stock, par value $0.0001 per share; 150,000,000 shares authorized, 33,548,366 and 33,181,197 shares issued and outstanding, respectively	3	3
Additional paid-in capital	39,870	39,473
Accumulated deficit	-41,222	-39,379
Total stockholders’ (deficit) equity	-1,349	97
Total liabilities and stockholders’ equity (deficit)	$1,678	$2,629

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Office equipment, accumulated depreciation (in dollars)	$24	$23
Intangible assets, accumulated amortization (in dollars)	$115	$111
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	33,548,366	33,181,197
Common stock, shares outstanding	33,548,366	33,181,197

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Research and development	$815	$1,104
General and administrative	1,028	836
Total operating expenses	1,843	1,940
Loss from operations	-1,843	-1,940
Loss before provision for income taxes	-1,843	-1,940
Provision for income taxes	0	0
Net loss	($1,843)	($1,940)
Net loss per common share, basic and diluted (in dollars per share)	($0.06)	($0.07)
Weighted average shares outstanding (in shares)	33,300,379	27,325,378

CONDENSED_STATEMENT_OF_STOCKHO

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
In Thousands, except Share data
Balance at Dec. 31, 2014	$97	$3	$39,473	($39,379)
Balance (in shares) at Dec. 31, 2014		33,181,197
Stock-based compensation	83	0	83	0
Common stock issued as payment of services and consulting fees	27	0	27	0
Common stock issued as payment of services and consulting fees (in shares)		30,000
Exercise of warrants	287	0	287	0
Exercise of warrants (in shares)		337,169
Net loss	-1,843	0	0	-1,843
Balance at Mar. 31, 2015	($1,349)	$3	$39,870	($41,222)
Balance (in shares) at Mar. 31, 2015		33,548,366

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($1,843)	($1,940)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5	6
Stock-based compensation	110	339
Increase in operating assets:
Prepaid expenses	37	16
Increase in operating liabilities:
Accounts payable and accrued expenses	495	570
Cash used in operating activities	-1,196	-1,009
Cash flows from investing activities:
Acquisition of office equipment	-4	-2
Cash used in investing activities	-4	-2
Cash flows from financing activities:
Proceeds from exercise of warrants	287	0
Cash provided by financing activities	287	0
Net decrease in cash	-913	-1,011
Cash and cash equivalents, beginning of period	2,316	3,587
Cash and cash equivalents, end of period	$1,403	$2,576

BACKGROUND

BACKGROUND	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	NOTE 1 – BACKGROUND
	GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are an early-stage, pre-revenue, pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate and other cancers. We plan to develop a series of therapies based on our target-activated prodrug technology platform.
	Our primary focus at the present time is the clinical development of our lead compound, mipsagargin (formerly referred to as G-202), a novel therapeutic agent with a unique mechanism of action. We have completed a Phase Ia/Ib dose escalation, safety, tolerability and dose refinement study of mipsagargin, in which we treated a total of 44 patients (includes Phase Ia and Ib), including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease up to eleven months after initiation of treatment. We have completed a Phase II clinical trial of mipsagargin in patients with liver cancer, in which twenty-five patients were treated. In January 2015, we announced results from our Phase II study in liver cancer patients which indicated that study participants experienced a median time to progression of 4.2 months, nearly twice the time demonstrated in prior studies with placebo or ineffective agents. Thirty-five percent of patients received five or more cycles of treatment with an average time on study of 7.1 months. These results support our plans to continue the development of mipsagargin for patients with liver cancer, as well as proceed with our clinical development strategy in other indications including glioblastoma, prostate cancer and renal cell carcinoma trials. Notwithstanding that the data from our trials appear promising, the outcome of our trials is uncertain and our current or future trials may ultimately be unsuccessful.
	We are currently conducting a Phase II clinical trial in glioblastoma (a type of brain cancer), in which twelve patients have been treated as of May 1, 2015. We also anticipate commencing the enrollment of patients in our Phase II clinical trials in patients with prostate cancer and initiating our planned Phase II clinical trial in patients with renal cell carcinoma.

MANAGEMENTS_PLANS_TO_CONTINUE_

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN	3 Months Ended
	Mar. 31, 2015
Management Plans to Continue as Going Concern [Abstract]
Management Plans to Continue as Going Concern Disclosure [Text Block]	NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN
	Basis of Presentation
	We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have an accumulated deficit of $41.2 million as of March 31, 2015. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our therapeutic product candidates which are currently in development or we enter into cash flow positive business development transactions.
	To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance mipsagargin through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds.
	Our cash and cash equivalents balance at March 31, 2015 was $1.4 million, representing 84% of our total assets. Based upon our current expected level of operating expenditures, we expect to be able to fund our operations for the next three to six months. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through collaborative arrangements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such collaborative arrangement will be entered into or that financing will be available when needed in order to allow us to continue our operations, or if available, on terms acceptable to us.
	In the event financing is not obtained, we may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
	Our auditors’ report issued in connection with our a December 31, 2014 financial statements expressed an opinion that our capital resources as of the date of their Audit Report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Accordingly, our current cash level raises substantial doubt about our ability to continue as a going concern past June 2015. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

SUMMARY_OF_CRITICAL_ACCOUNTING

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES
	Use of estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.
	Research and Development
	Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses.
	We incurred research and development expenses of approximately $0.8 million and $1.1 million for the three months ended March 31, 2015 and 2014, respectively.
	Loss per Share
	Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2015 and 2014, as they would be anti-dilutive:
		Three months ended March 31,
		2015	2014
	Shares underlying options outstanding	8,853,695	8,334,895
	Shares underlying warrants outstanding	19,401,382	10,001,591
	Shares underlying convertible notes outstanding	272,514	263,695
		28,527,591	18,600,181
	Fair Value of Financial Instruments
	Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.
	Fair Value Measurements
	Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:
	Level 1:  Quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2:  Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
	Level 3:  Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
	A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. As of March 31, 2015, the Company has no such assets or liabilities outstanding.
	Stock-Based Compensation
	We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).
	Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period.
	Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
	Recent Accounting Pronouncements
	In August 2014, the FASB issued Accounting Standards Update “ASU” 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This Update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this Update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting.
	In January 2015, the FASB issued ASU No. 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, simplifying the income statement presentation by eliminating the concept of extraordinary items. The guidance does not change the requirement to disclose items that are unusual in nature and occur infrequently. ASU No. 2015-01 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. Exclusive of a material transaction that would qualify for extraordinary item presentation in future periods, we do not expect the adoption of this standard to materially impact our financial statements.
	In April 2015, the Financial Accounting Standard Board issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. We do not expect the adoption of this standard to materially impact our consolidated financial statements.
	There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

SUPPLEMENTAL_CASH_FLOW_INFORMA

SUPPLEMENTAL CASH FLOW INFORMATION	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Information [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION
	The following table contains additional information for the periods reported (in thousands):
		Three months ended March 31,
		2015		2014
	Non-cash financial activities:
	Common stock options issued as payment of accrued compensation	$	—	$	962
	There was no cash paid for interest and income taxes for the three months ended March 31, 2015 and 2014.

ACCRUED_EXPENSES

ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCRUED EXPENSES
	Accrued expenses consist of the following (in thousands):
		March 31, 2015		December 31, 2014
	Accrued compensation and benefits	$	1,364	$	1,108
	Accrued research and development		138		163
	Accrued other		211		167
	Total accrued expenses	$	1,713	$	1,438

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	3 Months Ended
	Mar. 31, 2015
Notes Payable Disclosure [Abstract]
Notes Payable Disclosure [Text Block]	NOTE 6 – CONVERTIBLE NOTES PAYABLE
	We previously entered into convertible notes with our chief executive officer pursuant to which we borrowed an aggregate of $0.2 million, with $0.1 million principal balance outstanding at March 31, 2015. The notes, which bear interest at a rate of 4.2% per annum and matured at various dates through December 6, 2011, are now considered due on demand. As of March 31, 2015, our chief executive officer has not demanded the payment of the outstanding principal and accrued interest. Accrued interest at March 31, 2015 and December 31, 2014 was approximately $31,000 and $30,000, respectively. The notes and accrued interest are convertible, at the option of the holder, into shares of our common stock at a conversion price of $0.50 per share.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 7 – COMMITMENTS AND CONTINGENCIES
	Legal Matters
	On March 12, 2012, GenSpera instituted a declaratory judgment action against Annastasiah Mhaka (“Mhaka”) in the United States District Court for the District of Maryland: GenSpera, Inc. v. Mhaka, Civil Action No. MJG-12-772 (D. Md.). In its complaint, GenSpera, as the exclusive licensee of the inventions described and claimed in the U.S. Patent No. 7,468,354 (“the ‘354 patent”) and U.S. Patent No. 7,767,648 (“the ‘648 patent”), sought a declaratory judgment that Mhaka should not be added to either the ‘354 patent or the ‘648 patent as an inventor. On April 2, 2012, Mhaka filed and served her answer and counterclaim, in which she sought to be added as an inventor to the ‘354 patent and the ‘648 patent pursuant to 35 U.S.C. § 256. On November 1, 2012, Mhaka filed a second complaint in Maryland state court, asserting state tort claims against GenSpera and Drs. Samuel Denmeade and John Isaacs.
	On May 1, 2013, the District Court granted GenSpera’s motion for summary judgment in the original case. Reserving any ruling on the issue of whether Mhaka’s state law tort claims were preempted by federal patent law, the Court denied defendants’ motion to dismiss Mhaka’s complaint in the second case and directed Mhaka to re-file her claims as counterclaims in the original action. On May 14, 2013, Mhaka filed an amended answer and counterclaims in the consolidated action, re-pleading her tort claims as counterclaims. On June 3, 2013, GenSpera (along with Drs. Denmeade and Isaacs) filed a reply to the counterclaims, denying their allegations and raising a number of affirmative defenses. On January 2, 2014, Drs. Isaacs and Denmeade moved for summary judgment on the grounds that Mhaka’s tort claims were barred by the applicable statute of limitations, and GenSpera joined in the motion. On May 6, 2014, GenSpera moved separately for summary judgment, a motion that Drs. Denmeade and Isaacs joined in part. On September 12, 2014, the District Court granted GenSpera’s motion for summary judgment as well as the motion for summary judgment filed by Drs. Denmeade and Isaacs. Judgment in favor of GenSpera, Dr. Isaacs, and Dr. Denmeade was entered concurrently for purposes of both the original case and the second case.
	On October 10, 2014, Mhaka filed notices of Appeal with the United States Courts of Appeals for the Fourth Circuit and Federal Circuit. On December 11, 2014, GenSpera (along with Drs. Denmeade and Isaacs) filed a motion to dismiss the appeal before the United States Court of Appeals for the Fourth Circuit on the ground that the Court of Appeals for the Federal Circuit possesses exclusive jurisdiction over any appeal from the District Court. On December 29, 2014, Mhaka filed an opposition to the motion to dismiss and moved the Court of Appeals for the Fourth Circuit to stay appellate proceedings pending resolution of the appeal before the United States Court of Appeal for the Federal Circuit. On January 12, 2015, the Appellees filed an opposition to the motion to stay. On March 17, 2015, the Court of Appeals for the Fourth Circuit dismissed Mhaka’s appeal for lack of jurisdiction.
	In the appellate proceedings before the United States Court of Appeals for the Federal Circuit, Mhaka originally filed her opening brief on December 26, 2014. Mhaka filed a corrected opening brief on January 20, 2015. On February 12, 2015, the Appellees filed their responsive brief, and on March 16, 2015, Mhaka filed a reply brief. Oral argument on the appeal has yet to be scheduled

CAPITAL_STOCK_AND_STOCKHOLDERS

CAPITAL STOCK AND STOCKHOLDER'S EQUITY	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY
	Common Stock
	In March 2015, we also entered into an agreement to grant an aggregate of 30,000 shares of common stock, valued at approximately $27,000, to a consultant for business advisory services to be provided to the Company.
	During the three months ended March 31, 2015, 337,169 warrants were exercised into an equivalent number of common shares for which we received approximately $287,000 in proceeds. During the three months ended March 31, 2014, no warrants were exercised into common shares.

STOCK_OPTIONS

STOCK OPTIONS	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 9 – STOCK OPTIONS
	Our 2009 Executive Compensation Plan (“2009 Plan”) and our 2007 Equity Compensation Plan (“2007 Plan”) allow for the issuance of up to 6,000,000 shares of common stock each, or 12,000,000 in the aggregate. Collectively, the 2009 Plan and 2007 Plan are referred to as “the Plans.” Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of operations for the three months ended March 31, 2015 and 2014 was as follows:
		Three months ended March 31,
		2015			2014
	Research and development	$	10		$	6
	General and administrative		25			333
		$	35		$	339
	The following table summarizes stock option activity under the Plans:
		Number of		Weighted-			Weighted-average		Aggregate
		shares		average			remaining		intrinsic
				exercise			contractual term		value (in
				price			(in years)		thousands)
	Outstanding at December 31, 2014	8,685,095		$	1.65
	Granted	245,600		$	0.83
	Exercised	—			—
	Forfeited	-77,000		$	0.7
	Outstanding at March 31, 2015	8,853,695		$	1.62			3.8	$	143
	Exercisable at March 31, 2015	8,577,545		$	1.64			3.8	$	134
	As of March 31, 2015, there was approximately $92,000 of total unrecognized compensation cost related to non-vested stock options which vest over a weighted-average period of approximately one year. As of March 31, 2015, there was no unrecognized compensation expense related to performance-based, non-vested employee stock options.
	During the three months ended March 31, 2015, we issued options to purchase 53,000 shares of common stock to non-employee directors under the Plans. Additionally, we issued options to purchase 192,600 shares of common stock to consultants and advisors. During the three months ended March 31, 2014, we issued options to purchase 1,948,902 and 38,000 shares of common stock to employees and non-employee directors, respectively, under the Plans. Additionally, we issued options to purchase 297,370 shares of common stock to consultants and advisors. During the three months ended March 31, 2015 and 2014, no options were exercised.
	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2015 and 2014:
		Three months ended March 31,
		2015		2014
	Volatility	56.6	%	56	%
	Expected term (years)	3.7		3.4
	Risk-free interest rate	1	%	0.5	%
	Dividend yield	0	%	0	%

WARRANTS

WARRANTS	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 10 – WARRANTS
	We account for common stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock by the Company are at a lower price per share than the then-current warrant exercise price. As of March 31, 2015, there were no outstanding liability-classified warrants.
	Transactions involving our equity-classified warrants are summarized as follows:
		Number of	Weighted-		Weighted-average	Aggregate
		shares	average		remaining	intrinsic
			exercise		contractual term	value (in
			price		(in years)	thousands)
	Outstanding at December 31, 2014	19,897,928	$	1.61
	Granted	150,000	$	0.65
	Exercised	-337,169	$	0.85
	Forfeited	-309,377	$	3.1
	Outstanding at March 31, 2015	19,401,382	$	1.59	2	$	41
	Exercisable at March 31, 2015	19,401,382	$	1.59	2	$	41
	During the three months ended March 31, 2015, 337,169 warrants were exercised into an equivalent number of common shares for which we received approximately $287,000 in proceeds. During the three months ended March 31, 2014, no warrants were exercised.The following table summarizes outstanding common stock purchase warrants as of March 31, 2015:
		Number of	Weighted-		Expiration
		shares	average
			exercise
			price
	Issued to consultants	1,195,759	$	2.02	May 2015 through January 2020
	Issued pursuant to 2010 financings	713,566	$	3.5	May-15
	Issued pursuant to 2011 financings	1,936,785	$	3.24	January 2016 through April 2016
	Issued pursuant to 2012 financings	296,366	$	3	Dec-17
	Issued pursuant to 2013 financings	4,376,228	$	1.97	December 2017 through August 2018
	Issued pursuant to 2014 financings	10,882,678	$	0.93	December 2015 through June 2019
		19,401,382
	During the three months ended March 31, 2015, we issued warrants to consultants to purchase 150,000 shares of common stock as compensation for business and advisory services. The common stock purchase warrants have an exercise price of $0.65 per share, are immediately exercisable and expire on the five year anniversary of the date of issuance. The per share weighted-average fair value of the warrants granted to consultants during 2015 was estimated at $0.32 per share on the date of grant. During the three months ended March 31, 2014, we issued warrants to consultants to purchase 96,000 shares of common stock as compensation for business and advisory services. The common stock purchase warrants have an exercise price of $3.00 per share, are immediately exercisable and expire on the five year anniversary of the date of issuance. The per share weighted-average fair value of the warrants granted to consultants during 2014 was estimated at $0.41 per share on the date of grant. Total stock-based compensation expense of approximately $48,000 and $40,000 was recognized for warrants and included in the statement of operations for the three months ended March 31, 2015 and 2014, respectively.

SUMMARY_OF_CRITICAL_ACCOUNTING1

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Development
	Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses.
	We incurred research and development expenses of approximately $0.8 million and $1.1 million for the three months ended March 31, 2015 and 2014, respectively.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share
	Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2015 and 2014, as they would be anti-dilutive:
		Three months ended March 31,
		2015	2014
	Shares underlying options outstanding	8,853,695	8,334,895
	Shares underlying warrants outstanding	19,401,382	10,001,591
	Shares underlying convertible notes outstanding	272,514	263,695
		28,527,591	18,600,181
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements
	Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:
	Level 1:  Quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2:  Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
	Level 3:  Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
	A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. As of March 31, 2015, the Company has no such assets or liabilities outstanding.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).
	Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period.
	Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In August 2014, the FASB issued Accounting Standards Update “ASU” 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This Update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this Update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting.
	In January 2015, the FASB issued ASU No. 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, simplifying the income statement presentation by eliminating the concept of extraordinary items. The guidance does not change the requirement to disclose items that are unusual in nature and occur infrequently. ASU No. 2015-01 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. Exclusive of a material transaction that would qualify for extraordinary item presentation in future periods, we do not expect the adoption of this standard to materially impact our financial statements.
	In April 2015, the Financial Accounting Standard Board issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. We do not expect the adoption of this standard to materially impact our consolidated financial statements.
	There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

SUMMARY_OF_CRITICAL_ACCOUNTING2

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2015 and 2014, as they would be anti-dilutive:
		Three months ended March 31,
		2015	2014
	Shares underlying options outstanding	8,853,695	8,334,895
	Shares underlying warrants outstanding	19,401,382	10,001,591
	Shares underlying convertible notes outstanding	272,514	263,695
		28,527,591	18,600,181

SUPPLEMENTAL_CASH_FLOW_INFORMA1

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The following table contains additional information for the periods reported (in thousands):
		Three months ended March 31,
		2015		2014
	Non-cash financial activities:
	Common stock options issued as payment of accrued compensation	$	—	$	962

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following (in thousands):
		March 31, 2015		December 31, 2014
	Accrued compensation and benefits	$	1,364	$	1,108
	Accrued research and development		138		163
	Accrued other		211		167
	Total accrued expenses	$	1,713	$	1,438

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of operations for the three months ended March 31, 2015 and 2014 was as follows:
		Three months ended March 31,
		2015			2014
	Research and development	$	10		$	6
	General and administrative		25			333
		$	35		$	339
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity under the Plans:
		Number of		Weighted-			Weighted-average		Aggregate
		shares		average			remaining		intrinsic
				exercise			contractual term		value (in
				price			(in years)		thousands)
	Outstanding at December 31, 2014	8,685,095		$	1.65
	Granted	245,600		$	0.83
	Exercised	—			—
	Forfeited	-77,000		$	0.7
	Outstanding at March 31, 2015	8,853,695		$	1.62			3.8	$	143
	Exercisable at March 31, 2015	8,577,545		$	1.64			3.8	$	134
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2015 and 2014:
		Three months ended March 31,
		2015		2014
	Volatility	56.6	%	56	%
	Expected term (years)	3.7		3.4
	Risk-free interest rate	1	%	0.5	%
	Dividend yield	0	%	0	%

WARRANTS_Tables

WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Share-based Compensation, Activity [Table Text Block]	Transactions involving our equity-classified warrants are summarized as follows:
		Number of	Weighted-		Weighted-average	Aggregate
		shares	average		remaining	intrinsic
			exercise		contractual term	value (in
			price		(in years)	thousands)
	Outstanding at December 31, 2014	19,897,928	$	1.61
	Granted	150,000	$	0.65
	Exercised	-337,169	$	0.85
	Forfeited	-309,377	$	3.1
	Outstanding at March 31, 2015	19,401,382	$	1.59	2	$	41
	Exercisable at March 31, 2015	19,401,382	$	1.59	2	$	41
Schedule of Outstanding Warrants to Purchase Common Stock [Table Text Block]	The following table summarizes outstanding common stock purchase warrants as of March 31, 2015:
		Number of	Weighted-		Expiration
		shares	average
			exercise
			price
	Issued to consultants	1,195,759	$	2.02	May 2015 through January 2020
	Issued pursuant to 2010 financings	713,566	$	3.5	May-15
	Issued pursuant to 2011 financings	1,936,785	$	3.24	January 2016 through April 2016
	Issued pursuant to 2012 financings	296,366	$	3	Dec-17
	Issued pursuant to 2013 financings	4,376,228	$	1.97	December 2017 through August 2018
	Issued pursuant to 2014 financings	10,882,678	$	0.93	December 2015 through June 2019
		19,401,382

MANAGEMENTS_PLANS_TO_CONTINUE_1

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN (Details Textual) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Management Plan [Line Items]
Deficit accumulated during the development stage	$41,222	$39,379
Cash and Cash Equivalents, at Carrying Value	$1,403	$2,316	$2,576	$3,587
Percentage of Cash and Cash Equivalents in Total Assets	84.00%

SUMMARY_OF_CRITICAL_ACCOUNTING3

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	28,527,591	18,600,181
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	272,514	263,695
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	19,401,382	10,001,591
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	8,853,695	8,334,895

SUMMARY_OF_CRITICAL_ACCOUNTING4

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Summary Of Critical Accounting Policies [Line Items]
Research and Development Expense, Total	$815	$1,104

SUPPLEMENTAL_CASH_FLOW_INFORMA2

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Non-cash financial activities:
Common stock options issued as payment of accrued compensation	$0	$962

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accrued Expenses [Line Items]
Accrued compensation and benefits	$1,364	$1,108
Accrued research and development	138	163
Accrued other	211	167
Total accrued expenses	$1,713	$1,438

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term Debt, Gross	$100,000
Debt Instrument, Interest Rate, Effective Percentage	4.20%
Debt Instrument, Maturity Date	6-Dec-11
Debt Instrument, Increase, Accrued Interest	31,000	30,000
Debt Instrument, Convertible, Conversion Price	$0.50
Chief Executive Officer [Member]
Debt Instrument [Line Items]
Convertible Notes Payable, Total	$200,000

CAPITAL_STOCK_AND_STOCKHOLDERS1

CAPITAL STOCK AND STOCKHOLDER'S EQUITY (Details Textual) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued for Services	$27
Number of Warrants Exercised	337,169	0
Proceeds from Warrant Exercises	287	0
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services	30,000
Stock Issued During Period, Value, Issued for Services	$0
Number of Warrants Exercised	337,169

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$35	$339
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	10	6
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$25	$333

STOCK_OPTIONS_Details_1

STOCK OPTIONS (Details 1) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding at beginning of period (in shares)	8,685,095
Number of shares, Granted (in shares)	245,600
Number of shares, Exercised (in shares)	0	0
Number of shares, Forfeited (in shares)	-77,000
Number of shares, Outstanding at end of period (in shares)	8,853,695
Number of shares, Exercisable at December 31, 2014 (in shares)	8,577,545
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$1.65
Weighted-average exercise price, Granted (in dollars per share)	$0.83
Weighted-average exercise price, Exercised (in dollars per share)	$0
Weighted-average exercise price, Forfeited (in dollars per share)	$0.70
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	$1.62
Weighted-average exercise price, Exercisable at December 31, 2014 (in dollars per share)	$1.64
Weighted-average remaining contractual term, Outstanding at December 31, 2014	3 years 9 months 18 days
Weighted-average remaining contractual term, Exercisable at December 31, 2014	3 years 9 months 18 days
Aggregate intrinsic value, Outstanding at December 31, 2014 (in dollars)	$143
Aggregate intrinsic value, Exercisable at December 31, 2014 (in dollars)	$134

STOCK_OPTIONS_Details_2

STOCK OPTIONS (Details 2) (Employee Stock Option [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	56.60%	56.00%
Expected term (years)	3 years 8 months 12 days	3 years 4 months 24 days
Risk-free interest rate	1.00%	0.50%
Dividend yield	0.00%	0.00%

STOCK_OPTIONS_Details_Textual

STOCK OPTIONS (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$92,000
Share Based Compensation Arrangement Options Issued To Non Employee Directors	53,000	38,000
Share Based Compensation Arrangement Options Issued To Consultants	192,600	297,370
Share Based Compensation Arrangement Options Issued To Employee Directors		1,948,902
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,000,000
Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	12,000,000

WARRANTS_Details

WARRANTS (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding at beginning of period (in shares)	19,897,928
Number of shares, Granted (in shares)	150,000
Number of shares, Exercised (in shares)	-337,169
Number of shares, Forfeited (in shares)	-309,377
Number of shares, Outstanding at ending of period (in shares)	19,401,382
Number of shares, Exercisable at December 31, 2014 (in shares)	19,401,382
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$1.61
Weighted-average exercise price, Granted (in dollars per share)	$0.65
Weighted-average exercise price, Exercised (in dollars per share)	$0.85
Weighted-average exercise price, Forfeited (in dollars per share)	$3.10
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	$1.59
Weighted-average exercise price, Exercisable at December 31, 2014 (in dollars per share)	$1.59
Weighted-average remaining contractual term, Outstanding	2 years
Weighted-average remaining contractual term, Exercisable at December 31, 2014	2 years
Aggregate intrinsic value, Outstanding (in dollars)	$41
Aggregate intrinsic value, Exercisable at December 31, 2014 (in dollars)	$41

WARRANTS_Details_1

WARRANTS (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015
Equity-classified warrants [Abstract]
Number of shares (in shares)	19,401,382
Equity Classified Warrants [Member] | Consultant [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	1,195,759
Weighted Average Exercise price (in dollars per share)	$2.02
Investment Warrants Expiration Date Range Start	31-May-15
Investment Warrants Expiration Date Range End	31-Jan-20
Equity Classified Warrants [Member] | Financing 2010 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	713,566
Weighted Average Exercise price (in dollars per share)	$3.50
Investment Warrants Expiration Date	31-May-15
Equity Classified Warrants [Member] | Financing 2011 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	1,936,785
Weighted Average Exercise price (in dollars per share)	$3.24
Investment Warrants Expiration Date Range Start	31-Jan-16
Investment Warrants Expiration Date Range End	30-Apr-16
Equity Classified Warrants [Member] | Financing 2012 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	296,366
Weighted Average Exercise price (in dollars per share)	$3
Investment Warrants Expiration Date	31-Dec-17
Equity Classified Warrants [Member] | Financing 2013 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	4,376,228
Weighted Average Exercise price (in dollars per share)	$1.97
Investment Warrants Expiration Date Range Start	31-Dec-17
Investment Warrants Expiration Date Range End	31-Aug-18
Equity Classified Warrants [Member] | Financing 2014 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	10,882,678
Weighted Average Exercise price (in dollars per share)	$0.93
Investment Warrants Expiration Date Range Start	31-Dec-15
Investment Warrants Expiration Date Range End	30-Jun-19

WARRANTS_Details_Textual

WARRANTS (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Warrants And Derivative Warrant Liability [Line Items]
Warrants Exercised	337,169	0
Proceeds from Warrant Exercises	$287,000	$0
Share Based Compensation Expense Recognized For Warrants Issued To Consultants	$48,000	$40,000
Common Stock [Member]
Warrants And Derivative Warrant Liability [Line Items]
Warrants Exercised	337,169
Consultants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	150,000	96,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.65	$3
Warrants Weighted Average Fair Value	0.32	0.41